Kornimate/medical-research-clean huggingface dataset:
myoelectric gutprint-crohn's disease

Conditions: Crohn Disease

Summary: a feasibility study for assessing and recording myoelectric activity in patients for early detection of flare in patients with crohn's disease and differentiating the myoelectric signals from crohn's disease patients in remission state and healthy controls.

crohn's disease (cd) patients can have a chronic, relapsing course with frequent flares despite aggressive therapy. flares are often difficult to predict. the goal of disease monitoring is to identify patients at risk for flare in order to treat earlier, with the hope of maintaining remission and avoiding irreversible bowel damage such as fistulas and strictures that may lead to surgery. although endoscopic visualization of the mucosa allows in some cases ability to predict flare and determine deep remission, this procedure is invasive and requires anesthesia and a bowel preparation, and is not without risk. abdominal pain, cramps and diarrhea are particularly common symptoms of cd, which are associated with alteration of gastrointestinal (gi) motility. thus better understanding of gi motility patterns in cd flare and remission states may be helpful for prediction of flare for guiding appropriate therapy. the goal of this study is to determine whether the motility patterns measured by the g-tech non-invasive, wireless patch system can provide useful insight for routine cd care. three g-tech patches will be placed on the patients' abdomen and they will be given an ipod touch to carry with them for the next 3-6 days. data from the patches is processed offline to obtain motility patterns of the stomach, small intestine and colon. these patterns represent a rich trove of data that can be studied in multiple ways to provide comparisons and insight. some examples are the overall strength of motor activity in each of the organs, the duration and rhythmicity, the correlation with meals, pain events and bowel movements, day to day variations and their correlation with symptoms, and diurnal effects.

Eligibility criteria:
inclusion criteria: * patients with crohn's disease and healthy subjects above the age of 18 who are able to give consent and follow direction. exclusion criteria: * patients or subjects under the age of 18, pregnant, and those unable to give consent or follow direction. * healthy subjects with gastrointestinal symptoms or history of gastrointestinal surgeries. * patients with severe crohn's disease due to complexity of disease, complication, and potential needs for surgery. * patients with bowel surgeries due to potential impact on the g-tech results. for similar reasons we will exclude patients on new medications (e.g. within 3 months of enrollment) known to alter gi motility but we will not exclude patients on stable doses or chronic gi motility agents as this mimics "real world" in which the g-tech patch will be used and we can learn the stability of the motility recordings over time in stable patients.
study of nst-6179 in healthy subjects

Conditions: Short Bowel Syndrome; Parenteral Nutrition Associated Liver Disease

Summary: a double-blind, randomized, placebo controlled, single and multiple oral dose study to assess safety and tolerability of single and multiple doses of nst-6179 in healthy male and female subjects.


Eligibility criteria:
inclusion criteria: 1. males or females, of any race, between 18 and 65 years of age, inclusive. 2. body mass index between 18.0 and 32.0 kg/m\^2, inclusive. 3. in good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ecg, vital signs measurements, and clinical laboratory evaluations (congenital non haemolytic hyperbilirubinemia \[eg, suspicion of gilbert's syndrome based on total and direct bilirubin\] is not acceptable) at screening and/or check in as assessed by the investigator (or designee). 4. females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception. 5. able to comprehend and willing to sign an icf and to abide by the study restrictions exclusion criteria (additional criteria available): 1. significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee). 2. history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed). 3. any of the following: 1. qt interval corrected for heart rate using fridericia's method (qtcf) \> 450 ms confirmed by repeat measurement. 2. qrs duration \> 110 ms confirmed by repeat measurement. 3. pr interval \> 220 ms confirmed by repeat measurement. 4. findings which would make qtc measurements difficult or qtc data uninterpretable. 5. history of additional risk factors for torsades de pointes (eg, heart failure, hypokalaemia, family history of long qt syndrome). 4. use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including st. john's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee). 5. use or intend to use any prescription medications/products other than hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives within 14 days prior to dosing, unless deemed acceptable by the investigator (or designee). 6. participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days prior to dosing. 7. vegetarians, vegans, and/or unable to consume the high fat breakfast (subjects participating in a food effect evaluation only). 8. history of alcoholism or drug/chemical abuse within 2 years
prevalence of hypertension in type-2 diabetes mellitus

Conditions: Prevalence of Elevated Blood Pressure in Type-2 Diabetics

Summary: cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. hypertension has been confirmed as a major risk factor for cardiovascular disease, which is frequently associated with diabetes mellitus. therefore, the detection and management of elevated blood pressure (bp) is a critical component of the comprehensive clinical management of diabetics. since the rates of hypertension in diabetics are lacking in afghanistan, this study aimed to evaluate the prevalence of elevated blood pressure in type-2 diabetic patients.

cardiovascular disease is the most prevalent cause of morbidity and mortality in diabetic patients. hypertension has been confirmed as a major risk factor for cardiovascular disease, which is frequently associated with diabetes mellitus. therefore, the detection and management of elevated blood pressure (bp) is a critical component of the comprehensive clinical management of diabetics. since the rates of hypertension in diabetics are lacking in afghanistan, this study aimed to evaluate the prevalence of elevated blood pressure in type-2 diabetic patients. this is a descriptive cross-sectional study, which included 322 type -2 diabetic patients (37 male, 63 female) who were presented to our center from november 2019 to january 2020.

Eligibility criteria:
inclusion criteria: * clinically diagnosed diabetic patients * newly diagnosed diabetics * known case of diabetes exclusion criteria: * the patients who were seriously ill * pregnant women * type-1 diabetic patients,

Keywords: prevalence; hypertension; type-2 diabetes
use of self-management group to improve quality of life in patients with low vision

Conditions: Age Related Macular Degeneration

Summary: 120 patients with visual acuity \<6/12 will be randomized to receive either usual care or participate in a 6-week, 2 hour 'living with vision loss' program led by trained leaders. we hypothesize that a structured self-management low-vision rehabilitation program provides a greater improvement in participation in daily activities, and improves quality of life in vision-impaired people compared to the provision of the usual low vision rehabilitation services. we also plan to document barriers that prevent patients with low vision (visual acuity \<6/12) from participating in self-management course.


Eligibility criteria:
inclusion criteria: * clients who have attended the meei vision rehabilitation for the first time within 12 months * visual acuity of \<6/12 in the better eye with habitual correction * age 55+ years * living independently (not in a nursing home) * english speaking * no cognitive impairment * adequate hearing to respond to normal conversation exclusion criteria: * vestibular disease

Keywords: amd vision loss self-management strategies low-vision rehabilitation ivi
effect of s-adenosyl methionine treatment on recurrence after curative resection of hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the aim of this study is to explore the effect of s-adenosyl methionine on recurrence after curative resection of hepatocellular carcinoma.

hepatocellular carcinoma (hcc) is now a major health problem. although the recent advances in treatment of hcc have significantly improved the prognosis of patients with hcc, the overall survival rate is still unsatisfactory; the 5-year survival rate is only 50-70% even after curative treatment such as hepatic resection and percutaneous radiofrequency ablation. one of the reasons for the poor prognosis of hcc is its high rate of recurrence.however,anti-relapse treatment remains a pressing work to do. in recent years, some study reported that s-adenosyl methionine had an impact on promoting apoptosis and inhibiting the growth on breast cancer, colon cancer,gastric cancer and liver cancer in vitro and vivo. in this study, we aim to examine whether s-adenosyl methionine have an effect on improving patients' recurrence after curative resection of hepatocellular carcinoma.

Eligibility criteria:
inclusion criteria: * male or female patients \> 18 years and \<=70 years of age * patients preoperatively diagnosed of hepatocellular carcinoma according to the criteria of american association for the study of liver diseases(aasld) * within milan criteria * without or mild liver cirrhosis and the liver function is child a class. * without any other treatments such as tace、pei、prfa before the surgery * no evidence for extrahepatic metastasis exclusion criteria: * patients with macro tumor thrombus or extrahepatic metastasis. * patients with apparent cardiac, pulmonary, cerebral and renal dysfunction. * subjects accepting other trial drugs or participating in other clinical trials. * patients refuse to join our trial. * female with pregnancy or during the lactation period.

Keywords: s-adenosyl methionine recurrence
viability of pulsioflex monitoring in icu

Conditions: Cardiogenic Shock

Summary: goal of the study is to study the precision of semi-invasive cardiac index monitoring by means of the proaqt (pulsion medical systems se) sensor, whereby the pulmonary artery catheter will serve as gold standard.

goal of the study is to study the precision of semi-invasive cardiac index monitoring by means of the proaqt (pulsion medical systems se) sensor, whereby the pulmonary artery catheter will serve as gold standard. measurements will be performed contemporaly with both devices every 4 hours and all clinical and hemodynmaic parameters will be recorded, including but not limited to central venous pressure, wege pressure, mechanical ventilation pressures, blood pressures, volume balance as well as vasoaktive medikation doses. this precise evaluation shall serve to evaluate the precision of the proaqt to estimate the cardiac index under different clinical situation in the intensive care unit. a precision difference of below 30% between both methods will be regarded as clinically irrelevant, suggesting equipoise between both methods.

Eligibility criteria:
inclusion criteria: * in situ pulmonary artery catheter * above 16 years of age * at least 36 hours of continuous hemodynamic monitoring with the pulmonary artery catheter planed exclusion criteria: * patients with: * permanent or pesisting atrial fibrilation or ventricular arrythmias * moderate to severe aortic insuficiency or aortic stenosis * intravascular cardiac assist device * planed removal of the pulmonary artery catheter \<36 hours

Keywords: cardiac output cardiac index pulmonary artery catheter
sexual dysfunction in partner of patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis; Sexual Dysfunction

Summary: the adverse effects of rheumatologic diseases, especially ankylosing spondylitis (as), on sexual functions are known. the causes of sexual dysfunction in rheumatologic diseases are due to factors such as pain, weakness, fatigue, stiffness, functional disability, anxiety, depression, hormonal deficiency, drug use, decreased libido and poor body image. depending on these factors, sexual intercourse and frequency of sexual intercourse may decrease. sexual dysfunction may be seen in as due to physical and emotional problems caused by the disease.

there are many studies in the literature that determine sexual satisfaction and sexual dysfunction in individuals with as and compare individuals with as to healthy individuals . in the light of these studies, the investigators thought that the sexual function of partner of individuals with as may also be affected negatively. in the literature, no previous study examines the sexual function of partner of individuals with as. therefore, the aim was to determine the sexual function of partner of individuals with as and to compare with healthly adults of the same sex.

Eligibility criteria:
inclusion criteria: * being diagnosed with as for individuals with as, * no additional disease (comorbid and psychiatric disease, hypothyroidism, hypopituitarism, hypogonadism or hyperprolactinemia) * having a partner (relationship status in a monogamous sexual relationship), * not smoking and drinking, * non-as partner have not been diagnosed with as and their partner is as. exclusion criteria: * overweight or obesity (bmi \<28 kg / m2) * having had a pelvic injury, urological or gynecological operation in the last 3 months * hypogonadism; penile abnormalities such as hypospadias, congenital curvature or peyronie's disease with preserved penis stiffness * prostatic disorder * use of drugs that may affect erectile function (steroids, antihistamines, ß-blockers or ssris)

Keywords: ankylosing spondylitis sexual dysfunction
mtx discontinuation and vaccine response

Conditions: Arthritis, Rheumatoid

Summary: to investigate whether a short term discontinuation of methotrexate (mtx) will improve the vaccination efficacy to seasonal influenza vaccination without deteriorating ra disease activity in a randomized clinical trial.

rheumatoid arthritis (ra) is a chronic systemic inflammatory disease that affects the joints as the main target of the inflammation. patients with ra require chronic treatment with disease modifying anti-rheumatic drugs (dmards) including methotrexate (mtx), which constitutes the mainstay of treatment. underlying immune dysfunction and the additional immune suppression associated with treatment render patients with ra more susceptible to infection. thus, vaccination against preventable diseases including influenza, pneumococcal pneumonia and hepatitis b is recommended for all ra patients who are subject to treatment with immunesupprssive drugs, unless there is a contraindication to the use of vaccination. however, low dose of glucocorticoids, conventional dmards and biological dmards including tumor necrosis factor inhibitors have been reported to substantially decrease vaccine response (4); mtx has been reported to be associated with a decreased response to seasonal influenza vaccination by up to 15%. to optimize a vaccine response, vaccination should be administrated before the treatment with immunesuppressive medications is initiated. however, most patients with ra are already on stable dose of dmards at the time of when vaccinations, especially vaccine against seasonal influenza that needs annual administration, are considered. alternatively, temporarily discontinuation of dmards might restore normal immune response to and so improve the efficacy of vaccination. although a short term discontinuation of dmards during perioperative period has not been associated with increased disease activity the longer discontinuation of dmards might lead to a significant aggravation of ra disease activity. to optimize the vaccine response, a short term discontinuation of dmards could be considered if this approach proves to be safe and effective.

Eligibility criteria:
inclusion criteria: * males or females \> 18 years at time of consent * have a diagnosis of ra per acr criteria * must understand and voluntarily sign an informed consent form including writing consent for data protection * stable doses of methotrexate over the preceding 6 weeks exclusion criteria: * pregnant or lactating females * previous anaphylactic response to vaccine components or to egg. * acute infection with t \>38°c at the time of vaccination * history of guillain-barre syndrome or demyelinating syndromes * previous vaccination with any live vaccine 4 weeks before or any inactivated vaccine 2 weeks before the study * blood transfusion within 6 months * active rheumatoid arthritis necessitating a recent change in the drug regimen * any other rheumatic disease such as systemic lupus erythematosus, mixed connective tissue disease, dermatomyositis/polymyositis, and vasculitis except for secondary sjogren's disease
covid-19 versus neurological impairment, physical activity, social contacts and education

Conditions: Covid19; Neurological Disorder; Balance; Distorted; Gait Disorders, Neurologic; Activity, Motor; Social Isolation; Educational Problems; Quality of Life

Summary: the research will make it possible to assess patients who recovered from covid-19 for the incidence of neurological problems (impaired balance, gait, coordination, concentration and attention), and changes in the quality of life, physical activity, social contacts and education.

the intended size of group - 100 subjects (50 subjects - study group, 50 subjects - control group). the above population was determined based on sample size calculator, with the following parameters: fraction size of 0.9, confidence interval of 95%, maximum error of 9%. the proper study will be preceded with a pilot study involving a smaller group of subjects (in order to standardise the surveys, and minimise the relationship between the results of the survey and side-effect factors). after inclusion and exclusion criteria are considered, the subjects will be allocated into two groups: * study group (subjects who had tested positive and recovered from covid-19) * control group (healthy subjects who did not have covid-19). the controls will be matched to the study group for gender and age. the examination will be performed once, at the premises of the university of rzeszów. the participants' condition will be assessed using the following measures: * static and dynamic balance and risk of falls (force plate and computerised posturography, clinical tests) * activity in the cerebral cortex of the frontal lobe during focused performance of a task (hemoencephalography heg-system) * concentration and attention, memory and cognitive functions (bourdon-wiersma test and auditory-verbal learning test) * gait velocity and efficiency (10-meter walk test and 6-minute walk test) * physical activity (international physical activity questionnaire ipaq), as well as education, mood, and social contacts (specially designed questionnaire) * quality of life (sf-36 questionnaire)

Eligibility criteria:
inclusion criteria: * informed consent to participate in the study. * experienced infection with sars-cov-2. * age 19 - 26 years * no injuries to lower limbs in the period of 12 months preceding the date of enrolment into the study * no orthopaedic disorders affecting the lower limbs (including decreased length of the lower limbs) * no diagnosed neurological diseases or disorders (including labyrinth dysfunction) * no diagnosed impairment of concentration and attention exclusion criteria: * lack of informed consent to participate in the study * no experience of infection with sars-cov-2 * age outside the range of 19 and 27 years * confirmed injuries to lower limbs in the period of 12 months preceding the date of enrolment into the study * confirmed neurological diseases or disorders, such as impaired balance, concentration and attention.
identifying the anti-blood-clotting compounds in garlic

Conditions: Arteriosclerosis; Intracranial Arteriosclerosis

Summary: this study will seek to identify the compound(s) in garlic that is (are) responsible for its ability to prevent the formation of blood clots (prevent platelet aggregation) and to determine the maximally effective dose and duration of the benefits. this study will also determine whether "cooked" garlic (garlic powder added to boiling water, no allicin present) is as effective as "fresh" garlic (garlic powder added to ambient water, high allicin present) and, if more than one compound is involved, and whether their combined effects are more significant than the effects of each compound alone.

published studies indicate that various types of undefined garlic products display antiplatelet activity. however, the compounds responsible for this antiplatelet effect have not been identified. acute studies. in acute (one day) studies, healthy participants will consume several doses of "fresh garlic" (garlic powder added to ambient water; up to the equivalent of 12 grams fresh garlic or 52 mg allicin) as a paste in a tuna sandwich. at 0, 2, 4, and 6 hours after consumption, the ability of platelets to aggregate in platelet-rich plasma (prp) or in whole blood (wb), in response to a drug (collagen, adp) that stimulates platelet aggregation, will be measured. after establishing the optimum dose and optimum time of the antiplatelet effect for each person, and if the effects are sufficiently strong, the effects of cooked garlic (garlic powder added to boiling water, no allicin present) and seven extracted fractions (oil, protein, fructans, etc.) will be determined, using the fractions at the same dose as their abundance in the established optimum dose of crushed fresh garlic. chronic studies. if only weak platelet effects are found for a high acute dose of "fresh" garlic, chronic studies will be conducted. in chronic studies, participants will consume 8.0 grams of "fresh garlic" (2.7 grams garlic powder added to ambient water, allicin content = 35 mg) as a paste in a tuna sandwich every day for four weeks and 8.0 grams of "boiled garlic" (2.7 grams garlic powder added to boiling water) in a sandwich every day for an additional four weeks, after a 1-week washout. the ability of platelets to aggregate in prp and whole blood will be determined before and every week after garlic consumption begins and after the 1-week washout.

Eligibility criteria:
inclusion criteria: * body mass index of 19 to 30 kg/m2 * plans to remain in the study area for the next year * willingness to abstain from nonsteroidal anti-inflammatory drugs (nsaid drugs for 1 week prior to each study test * willingness to abstain from consuming garlic and significant amounts of onion, chocolate, or purple grape juice for 3 days prior to each study test * willingness to participate in all study tests exclusion criteria: * pregnancy or breast-feeding * serious medical condition * allergy to garlic or wheat * tobacco use * excessive alcohol consumption * under psychiatric care

Keywords: garlic